Medication use and survival in diabetic patients with kidney cancer: A population-based cohort study

Pharmacological Research

Volumn 113, Issue , 2016, Pages 468-474

  Nayan, Madhur ^a   Macdonald, Erin M ^b   Juurlink, David N ^b,c   Austin, Peter C ^b,d,e   Finelli, Antonio ^a   Kulkarni, Girish S ^a   Hamilton, Robert J ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e Canada   (Canada)

Author keywords

Anti inflammatory agents; Diabetes mellitus; Hydroxymethylglutaryl CoA reductase inhibitors; Kidney neoplasms; Metformin; Non steroidal; Survival

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; COHORT ANALYSIS; DRUG USE; FEMALE; HUMAN; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY RISK; NON INSULIN DEPENDENT DIABETES MELLITUS; ONTARIO; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; DIABETES MELLITUS; KIDNEY TUMOR; MORTALITY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL RATE;

AGED; ANTINEOPLASTIC AGENTS; DIABETES MELLITUS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84988731429     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.09.027     Document Type: Article

References (46)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics. CA: Cancer J. Clin. 65:1 (2015), 5–29.
2. [2] Znaor, A., Lortet-Tieulent, J., Laversanne, M., Jemal, A., Bray, F., International variations and trends in renal cell carcinoma incidence and mortality. Eur. Urol., 2014.
3. [3] Chow, W.H., Dong, L.M., Devesa, S.S., Epidemiology and risk factors for kidney cancer. Nat. Rev. Urol. 7:5 (2010), 245–257.
4. [4] De, P., Otterstatter, M.C., Semenciw, R., Ellison, L.F., Marrett, L.D., Dryer, D., Trends in incidence, mortality, and survival for kidney cancer in Canada. Cancer Causes Control, 2014, 1986–2007.
5. [5] Vavallo, A., Simone, S., Lucarelli, G., Rutigliano, M., Galleggiante, V., Grandaliano, G., Gesualdo, L., Campagna, M., Cariello, M., Ranieri, E., Pertosa, G., Lastilla, G., Selvaggi, F.P., Ditonno, P., Battaglia, M., Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma. Medicine (United States), 93(27), 2014.
6. [6] Ha, Y.S., Kim, W.T., Yun, S.J., Lee, S.C., Kim, W.J., Park, Y.H., Kang, S.H., Hong, S.H., Byun, S.S., Kim, Y.J., Multi-institutional analysis of localized renal cell carcinoma that demonstrates the impact of diabetic status on prognosis after nephrectomy. Ann. Surg. Oncol. 20:11 (2013), 3662–3668.
7. [7] Danaei, G., Finucane, M.M., Lu, Y., Singh, G.M., Cowan, M.J., Paciorek, C.J., Lin, J.K., Farzadfar, F., Khang, Y.-H., Stevens, G.A., National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2· 7 million participants. Lancet 378:9785 (2011), 31–40.
8. [8] Larsson, S.C., Wolk, A., Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies. Diabetologia 54:5 (2011), 1013–1018.
9. [9] Bao, C., Yang, X., Xu, W., Luo, H., Xu, Z., Su, C., Qi, X., Diabetes mellitus and incidence and mortality of kidney cancer: a meta-analysis. J. Diabetes Complications 27:4 (2013), 357–364.
10. [10] Nielsen, S.F., Nordestgaard, B.G., Bojesen, S.E., Statin use and reduced cancer-related mortality. New Engl. J. Med. 367:19 (2012), 1792–1802.
11. [11] Landman, G.W., Kleefstra, N., van Hateren, K.J., Groenier, K.H., Gans, R.O., Bilo, H.J., Metformin associated with lower cancer mortality in type 2 diabetes ZODIAC-16. Diabetes Care 33:2 (2010), 322–326.
12. [12] Nayan, M., Bhindi, B., Julie, L.Y., Hermanns, T., Mohammed, A., Hamilton, R.J., Finelli, A., Jewett, M.A., Zlotta, A.R., Fleshner, N.E., The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2015, Elsevier p. 386. e387-386. e313.
13. [13] Liao, X., Lochhead, P., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M., Imamura, Y., Qian, Z.R., Baba, Y., Shima, K., Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. New Engl. J. Med. 367:17 (2012), 1596–1606.
14. [14] Rini, B.I., Weinberg, V., Dunlap, S., Elchinoff, A., Yu, N., Bok, R., Simko, J., Small, E.J., Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 106:3 (2006), 566–575.
15. [15] Shinohara, N., Kumagai, A., Kanagawa, K., Maruyama, S., Abe, T., Sazawa, A., Nonomura, K., Multicenter phase II trial of combination therapy with meloxicam, a COX-2 inhibitor, and natural interferon-α for metastatic renal cell carcinoma. Jpn. J. Clin. Oncol. 39:11 (2009), 720–726.
16. [16] Hamilton, R.J., Morilla, D., Cabrera, F., Leapman, M., Chen, L.Y., Bernstein, M., Hakimi, A.A., Reuter, V.E., Russo, P., The association between statin medication and progression after surgery for localized renal cell carcinoma. J. Urol. 191:4 (2014), 914–919.
17. [17] Khimani, F., Shah, N., Curley, B.F., Newton, M.D., Hogan, T.F., Monga, M., Metformin use and renal cell cancer outcomes among patients with diabetes. J. Clin. Oncol., 2014.
18. [18] Shah, N., Khimani, F., Curley, B.F., Newton, M.D., Hogan, T.F., Wen, S., Hu, Y., Monga, M., Metformin use and survival in diabetic patients with renal cell carcinoma (RCC). J. Clin. Oncol., 2014.
19. [19] Psutka, S., Boorjian, S., Lohse, C., Stewart, S., Tollefson, M., Leibovich, B., Thompson, R.H., The effect of metformin in patients with surgically treated renal cell carcinoma. J. Urol., 2014, e579.
20. [20] Haake, S.M., Brooks, S.A., Welsh, E., Berglund, A., Fulp, W.J., Chen, D.T., Haura, E.B., Sexton, W.J., Spiess, P.E., Pow-Sang, J., Rathmell, K., Fishman, M.N., Molecular subtypes of clear cell renal cell carcinoma: impact of diabetes mellitus, metformin, and immunotherapy on patient outcomes. J. Clin. Oncol., 2014.
21. [21] Kaffenberger, S.D., Lin-Tsai, O., Stratton, K.L., Morgan, T.M., Barocas, D.A., Chang, S.S., Cookson, M.S., Herrell, S.D., Smith, J.A., Clark, P.E., Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, Elsevier p. 21. e11-21. e17.
22. [22] Viers, B.R., Thompson, R.H., Psutka, S.P., Lohse, C.M., Cheville, J.C., Leibovich, B.C., Tollefson, M.K., Boorjian, S.A., The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2015, Elsevier.
23. [23] Krane, L.S., Sandberg, J.M., Rague, J.T., Hemal, A.K., Do statin medications impact renal functional or oncologic outcomes for robot-assisted partial nephrectomy?. J. Endourol. 28:11 (2014), 1308–1312.
24. [24] Nayan, M., Finelli, A., Jewett, M., Juurlink, D., Austin, P., Kulkarni, G., Hamilton, R., Statin use and kidney cancer survival outcomes: a propensity score analysis. Urol. Oncol., 2016 http://www.ncbi.nlm.nih.gov/pubmed/27427224.
25. [25] Nayan, M., Finelli, A., Jewett, M., Juurlink, D., Austin, P., Kulkarni, G., Hamilton, R., Metformin use and kidney cancer outcomes in diabetics: a propensity score analysis. Clin. Genitourin. Cancer, 2016 http://www.ncbi.nlm.nih.gov/pubmed/27424258.
26. [26] Hux, J.E., Ivis, F., Flintoft, V., Bica, A., Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 25:3 (2002), 512–516.
27. [27] Brenner, D.R., Tammemagi, M.C., Bull, S.B., Pinnaduwaje, D., Andrulis, I.L., Using cancer registry data: agreement in cause-of-death data between the Ontario Cancer Registry and a longitudinal study of breast cancer patients. Chronic Dis. Can. 30:1 (2009), 16–19.
28. [28] Levy, A., O'Brien, B., Sellors, C., Grootendorst, P., Willison, D., Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can. J. Clin. Pharmacol., 10(2), 2003, 67.
29. [29] Juurlink, D.N., Canadian Institute for Health Information Discharge Abstract Database: a Validation Study. 2006, Institute for Clinical Evaluative Sciences.
30. [30] Warren, J.L., Barbera, L., Bremner, K.E., Yabroff, K.R., Hoch, J.S., Barrett, M.J., Luo, J., Krahn, M.D., End-of-life care for lung cancer patients in the United States and Ontario. J. Natl. Cancer Inst. 103:11 (2011), 853–862.
31. [31] Jang, R.W., Krzyzanowska, M.K., Zimmermann, C., Taback, N., Alibhai, S.M., Palliative care and the aggressiveness of end-of-life care in patients with advanced pancreatic cancer. J. Natl. Cancer Inst., 107(3), 2015, dju424.
32. [32] Margel, D., Urbach, D.R., Lipscombe, L.L., Bell, C.M., Kulkarni, G., Austin, P.C., Fleshner, N., Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J. Clin. Oncol. 31:25 (2013), 3069–3075.
33. [33] Lega, I.C., Austin, P.C., Gruneir, A., Goodwin, P.J., Rochon, P.A., Lipscombe, L.L., Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care 36:10 (2013), 3018–3026.
34. [34] Austin, P.C., van Walraven, C., Wodchis, W.P., Newman, A., Anderson, G.M., Using the Johns Hopkins Aggregated Diagnosis Groups (ADGs) to predict mortality in a general adult population cohort in Ontario, Canada. Med. Care 49:10 (2011), 932–939.
35. [35] Margel, D., Urbach, D., Fleshner, N., Austin, P.C., Reply to MMJ Zanders et al. J. Clin. Oncol., 32(7), 2014, 702.
36. [36] Sauerbrei, W., Meier-Hirmer, C., Benner, A., Royston, P., Multivariable regression model building by using fractional polynomials: description of SAS, STATA and R programs. Comput. Statistics & Data Anal. 50:12 (2006), 3464–3485.
37. [37] Iacovelli, R., Massari, F., Albiges, L., Loriot, Y., Massard, C., Fizazi, K., Escudier, B., Evidence and clinical relevance of tumor flare in patients who discontinue tyrosine kinase inhibitors for treatment of metastatic renal cell carcinoma. Eur. Urol. 68:July (1) (2014), 154–160.
38. [38] Nakai, Y., Isayama, H., Sasaki, T., Mizuno, S., Sasahira, N., Kogure, H., Kawakubo, K., Yamamoto, N., Hirano, K., Ijichi, H., Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. Pancreas 42:2 (2013), 202–208.
39. [39] Hakimi, A.A., Chen, L., Kim, P.H., Sjoberg, D., Glickman, L., Walker, M.R., Russo, P., The impact of metformin use on recurrence and cancer-specific survival in clinically localized high-risk renal cell carcinoma. Can. Urol. Assoc. J. 7:11-12 (2013), E687–691.
40. [40] Rothwell, P.M., Fowkes, F.G.R., Belch, J.F., Ogawa, H., Warlow, C.P., Meade, T.W., Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377:9759 (2011), 31–41.
41. [41] Jager, K., Zoccali, C., Macleod, A., Dekker, F., Confounding: what it is and how to deal with it. Kidney Int. 73:3 (2008), 256–260.
42. [42] Donat, S.M., Salzhauer, E.W., Mitra, N., Yanke, B.V., Snyder, M.E., Russo, P., Impact of body mass index on survival of patients with surgically treated renal cell carcinoma. J. Urol. 175:1 (2006), 46–52.
43. [43] Haferkamp, A., Pritsch, M., Bedke, J., Wagener, N., Pfitzenmaier, J., Buse, S., Hohenfellner, M., The influence of body mass index on the long-term survival of patients with renal cell carcinoma after tumour nephrectomy. BJU Int. 101:10 (2008), 1243–1246.
44. [44] Kamat, A.M., Shock, R.P., Naya, Y., Rosser, C.J., Slaton, J.W., Pisters, L.L., Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology 63:1 (2004), 46–50.
45. [45] Steffens, S., Von Klot, C., Eggers, H., Seidel, C., Wegener, G., Schrader, M., Kuczyk, M.A., Schrader, A.J., The role of diabetes mellitus and obesity in localized and metastatic RCC. Eur. Urol., 11(Suppl. 1), 2012 e1018-e1018a.
46. [46] Yood, M.U., Campbell, U.B., Rothman, K.J., Jick, S.S., Lang, J., Wells, K.E., Jick, H., Johnson, C.C., Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol. Drug Saf. 16:9 (2007), 961–968.